---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-002146"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:58:54.074400+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Profound Medical to present TULSA-PRO data at SIR 2026 in Toronto, April 11-15

## Summary
- Five oral presentations on April 12 during 'Men's Health 1' session at SIR Annual Meeting.
- Categorical course 'Prostate Interventions: TULSA and Beyond' on April 13 featuring TULSA.
- Presentations include CAPTAIN trial data comparing TULSA vs robotic prostatectomy for intermediate-risk prostate cancer.
- Other topics: TULSA for recurrent prostate cancer, extreme apex cancer, and automated segmentation validation.
- CEO says growing acceptance of TULSA as mainstream treatment for prostate disease.

## SEC filing metadata
- accession: 0001171843-26-002146
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/0001171843-26-002146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326002146/f8k_040126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-002146
- JSON: https://secwatch.observer/filing/0001171843-26-002146.json
- Plain text: https://secwatch.observer/filing/0001171843-26-002146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.